Cargando…

Recent advances in treating Parkinson’s disease

This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing...

Descripción completa

Detalles Bibliográficos
Autor principal: Oertel, Wolfgang H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357034/
https://www.ncbi.nlm.nih.gov/pubmed/28357055
http://dx.doi.org/10.12688/f1000research.10100.1
_version_ 1782515973109055488
author Oertel, Wolfgang H.
author_facet Oertel, Wolfgang H.
author_sort Oertel, Wolfgang H.
collection PubMed
description This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future.
format Online
Article
Text
id pubmed-5357034
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-53570342017-03-28 Recent advances in treating Parkinson’s disease Oertel, Wolfgang H. F1000Res Review This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future. F1000Research 2017-03-13 /pmc/articles/PMC5357034/ /pubmed/28357055 http://dx.doi.org/10.12688/f1000research.10100.1 Text en Copyright: © 2017 Oertel WH http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Oertel, Wolfgang H.
Recent advances in treating Parkinson’s disease
title Recent advances in treating Parkinson’s disease
title_full Recent advances in treating Parkinson’s disease
title_fullStr Recent advances in treating Parkinson’s disease
title_full_unstemmed Recent advances in treating Parkinson’s disease
title_short Recent advances in treating Parkinson’s disease
title_sort recent advances in treating parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357034/
https://www.ncbi.nlm.nih.gov/pubmed/28357055
http://dx.doi.org/10.12688/f1000research.10100.1
work_keys_str_mv AT oertelwolfgangh recentadvancesintreatingparkinsonsdisease